Abstract:The vascular endothelial growth factor receptor-2 kinases (VEGFR-2) expressed on tumor cells and vessels are attractive targets for cancer treatment. Potent inhibitors for the VEGFR-2 receptor are novel strategies to develop anti-cancer drugs. In this work, template ligand-based 3D-QSAR studies were performed on a series of benzoxazole derivatives toward different cell lines (HepG2, HCT-116 and MCF-7). Comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA) techniques were used to generate 3D-QSAR models. Good predictability was derived for the optimal CoMFA models (HepG2: R-cv(2) = 0.509, R-pred(2) = 0.5128; HCT-116: R-cv(2) = 0.574, R-pred(2) = 0.5597; MCF-7: R-cv(2) = 0.568, R-pred(2) = 0.5057) and CoMSIA models (HepG2: R-cv(2) = 0.711, R-pred(2) = 0.6198; HCT-116: R-cv(2) = 0.531, R-pred(2) = 0.5804; MCF-7: R-cv(2) = 0.669, R-pred(2) = 0.6577). In addition, the contour maps derived from CoMFA and CoMSIA models were also generated to illustrate the relationship between different fields and the inhibitory activities. Moreover, molecular docking and molecular dynamics (MD) simulations were also conducted to understand the binding modes and the potential interactions between the receptor and the inhibitors. Some key residues (Leu35, Val43, Lys63, Leu84, Gly117, Leu180 and Asp191) were pointed out for stabilizing the inhibitors in the binding pocket. The binding free energies for the inhibitors agreed well with the experimental inhibitory activity and indicated that steric, electrostatic and hydrogen bond interactions are the main driving force for inhibitor-receptor binding. Overall, a good consistency between theoretical 3D-SQAR and molecular docking and MD simulation studies would provide directions for the design of new candidates, avoiding time-consuming and costly synthesis and biological evaluations. On the whole, the results derived from this study could expand the understanding of benzoxazole derivatives as anticancer agents and would be of great help in lead optimization for early drug discovery of highly potent anticancer activity targeting VEGFR-2.

3D-Qsar of Benzothiazole Derivatives As Potent Anticancer Agents

3D-QSAR Study of AHMA Derivatives as Potent Anticancer Agents

A QSAR Study and Molecular Design of Benzothiazole Derivatives As Potent Anticancer Agents

DFT and 3D-QSAR Studies of Anti-Cancer Agents M-(4-morpholinoquinazolin-2-yl) Benzamide Derivatives for Novel Compounds Design

QSAR Research of Novel Tetrandrine Derivatives Against Human Hepatocellular Carcinoma.

A QSAR Study of Substituted Benzo[a]phenazines As Potential Anticancer Agents

3D-QSAR Study on a Series of Acridine Derivatives As DNA-binding Potential Antitumor Agents Using CoMFA and CoMSIA

3D-QSAR Study on a Series of Indolo[1,2-b]quinazoline Derivatives with Anticancer Activity and Their Molecular Design

Molecular simulation of a series of benzothiazole PI3Kα inhibitors: probing the relationship between structural features, anti-tumor potency and selectivity

3d-Qsar Study Of A Series Of Novel Benzofuran Nmt Inhibitors

Qsar and Molecular Design of Benzo[B] Acronycine Derivatives As Antitumor Agents

Comparative Molecular Field Analysis(CoMFA) of Curcumin-related Compounds for Anticancer Activity

2D and 3D‐QSAR Studies on Antiproliferative Thiazolidine Analogs

2D/3D-QSAR STUDY ON ANALOGUES OF 2-METHOXYESTRADIOL WITH ANTICANCER ACTIVITY

3D-QSAR Analysis on Benzoxazinone Derivatives

A 3D-QSAR Study on Betulinic Acid Derivatives as Anti-Tumor Agents and the Synthesis of Novel Derivatives for Modeling Validation.

<i>In silico</i> studies of a novel scaffold of benzoxazole derivatives as anticancer agents by 3D-QSAR, molecular docking and molecular dynamics simulations

3D-QSAR studies on quinazoline derivatives as EGFR-T790M inhibitors by Comparative Molecular Field Analysis (CoMFA)

3D-QSAR study on a series of Bcl-2 protein inhibitors using comparative molecular field analysis.

3D-QSAR Study for Inhibitors of Cyclin-Dependent Kinase 4

3D-QSAR study of a series of novel triazole antifungal compounds